Press Release Details

The 250,000 square-foot facility located in Cantanhede, Portugal serves as the hub for Tilray’s cultivation, processing, distribution and research of medical cannabis products in Europe

NANAIMO, British Columbia--(BUSINESS WIRE)--Apr. 24, 2019-- Tilray (NASDAQ:TLRY), a global pioneer in the research, cultivation, production and distribution of cannabis today celebrated the official opening of its European Union (EU) Campus located in Cantanhede, Portugal. Tilray CEO Brendan Kennedy, global senior leaders and the EU Campus Team welcomed guests from all over the world including international healthcare professionals, government officials and local dignitaries to celebrate the inauguration of the company’s European production and distribution centre.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190424005692/en/

Mayor of Oliveira do Hospital, José Carlos Alexandrino; International Advisory Board, Jaime Gama; President of INFARMED, Maria Do Céu Machado; President of AICEP, Luis Castro Henriques; Mayor of Cantanhede, Helena Teodósio; Brendan Kennedy, Tilray President and CEO; Secretary of State, Eurico Brilhante Dias (Photo: Business Wire)

For the event, which followed Tilray’s successful outdoor harvest last year and greenhouse harvest earlier this year, guests were invited to attend a ribbon-cutting ceremony and tour Tilray’s state-of-the-art facility.

Tilray’s EU Campus in Portugal is a multi-faceted production facility that includes indoor, outdoor and greenhouse cultivation sites, as well as research labs, processing, packaging and distribution sites for medical cannabis and cannabinoid-derived medical products. To date, Tilray has invested approximately €20 million in the facility, which totals approximately 250,000 square-feet with additional room to expand. Tilray’s EU Campus also serves as a hub supporting Tilray’s clinical research and product development efforts across Europe. Tilray’s EU Campus currently employs more than 100 professionals, and that number is expected to double by the end of 2019, with production ramping up and multiple harvests anticipated in the coming months.

“We’re thrilled to celebrate another milestone as we continue to expand our global presence and pioneer the future of the cannabis industry. We are grateful for the warm welcome we’ve received from Portugal and the city of Cantanhede,” says Brendan Kennedy, Tilray CEO. “We’re looking forward to utilizing Tilray’s EU Campus to serve the European Union medical cannabis markets with high-quality, pharmaceutical-grade medical cannabis products.”

Tilray announced a successful harvest from its EU Campus in February 2019 with multiple harvests expected in the coming months. Tilray looks forward to supplying patients in Europe from its EU Campus when it receives GMP certification.

About Tilray®
Tilray is a global pioneer in the research, cultivation, production and distribution of cannabis currently serving tens of thousands of patients in twelve countries spanning five continents.

Cautionary note regarding forward-looking statements:
This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of Canadian securities laws, or collectively, forward-looking statements. Forward-looking statements in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions, including statements in respect to Tilray’s medical cannabis products and the future performance of its European Union Campus. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment and future approvals and permits. Actual results, performance or achievement could differ materially from that expressed in, or implied by, any forward-looking statements in this press release, and, accordingly, you should not place undue reliance on any such forward-looking statements and they are not guarantees of future results. Please see the heading “Risk Factors” in Tilray’s Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission and Canadian securities regulators on March 25, 2019, assumptions, uncertainties and other factors that may cause actual future results or anticipated events to differ materially from those expressed or implied in any forward-looking statements. Tilray does not undertake and specifically declines any obligation to update any forward-looking statements that are included herein, except in accordance with applicable securities laws.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190424005692/en/

Source: Tilray

Media: Chrissy Roebuck, +1-833-206-8161, news@tilray.com
Investors: Katie Turner, +1-646-277-1228, Katie.turner@icrinc.com